… name Ilaris is a medication for the treatment … ILARIS (canakinumab) received US Food and Drug Administration (FDA … trials information of Ilaris covering trial interventions, trial conditions, trial … KEYWORD: HEALTH PHARMACEUTICAL SOURCE: Research and …

… pharmaceutical company, said on 6 November 2020 that its drug … to Novartis, this medicine, approved as Ilaris for juvenile arthritis and … by inflammatory reactions. This trial, in 454 patients in … 19 drug candidate that is due to enter clinical trials soon …

… drug could be repurposed during the pandemic. The medicine, approved as Ilaris … by inflammatory reactions. The trial, in 454 patients in … another late-stage trial of its drug Jakavi against COVID … coronavirus drug candidate that is due to enter clinical trials …

… under the brand name Ilaris for the treatment of Cryopyrin Associated Periodic … , Sancilio Pharmaceuticals announced that it has received the European Medicines Agencys (EMA … the treatment of sickle cell disease. The US Food and Drug Administration (FDA …

… of Internal Medicine revealed that the drug canakinumab, also known as Ilaris, usually … was derived from a large trial. The result pointed to a … ;potential new pathway in the treatment of osteoarthritis." The findings …

… osteoarthritis. However, the trial — funded by Ilaris-maker Novartis — has … new pathway in the treatment of osteoarthritis." … a few small clinical trials have tested various IL … medications. Half of the patients were randomly assigned to take the drug …

… encouraging note for new drug approvals despite the ongoing … 16, Novartis' Ilaris, the first treatment for adult-onset Still … mention is the FDA approval of Ultragenyx Pharmaceutical Inc.'s … a look at the biotech stocks facing FDA decision in July. …

… its paces as a possible treatment for the runaway inflammation that … of the CANTOS trial failed to convince the FDA that Ilaris could be … . The drug is, however, still in the late-stage CANOPY trials programme …

… Drug Administration Tuesday approved Novartis AG's (NVS) Ilaris for the treatment … , patients had no FDA-approved treatments for their disease, … Transplant Medicine in the FDA's Center for Drug … arthritis and rash, the FDA said. For comments and …

The FDA approves Novartis' (NVS +1.6%) Ilaris (canakinumab) for the treatment of … , rash and joint pain. The FDA originally approved the interleukin-1 …